Cure My Disease

Don't miss your cure!

 Log in / Sign up

Labor-Shortening drug showdown: which works best for First-Time moms?

NCT ID NCT07474350

Symptom relief Sponsor: Federal Teaching Hospital Abakaliki Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two medications, valethamate bromide and hyoscine butyl bromide, to see which one helps first-time mothers have shorter labor. 165 women in Nigeria took part. The goal was to speed up cervical dilation during active labor. Results can help doctors choose the better option for a faster delivery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

165 people

The number who actually took part.

Started

Sep 2023

Finished

Jan 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primigravidae / nulliparae. * Singleton term pregnancy with no evidence of maternal or fetal distress. * Women with fetus in cephalic presentation. * Age: 18- 35 years. * Women with no contra-indications to vaginal delivery. * Cervical dilatations of 4- 9cm when in labour * Spontaneous or induced labour. * Patients on epidural analgesia Exclusion Criteria: * Multiple gestations. * Women with abnormal fetal presentation. * Absolute indications for caesarean section. * Antepartum hemorrhage. * Evidence of maternal or fetal distress. * Fibroid in pregnancy. * Grand multiparous patients. * Previous uterine scar/ surgery or ruptures. * Medical disorders of pregnancy like pre-eclempsia, Eclempsia, Dm etc. * If any other antispasmodics agent had been used within the last 48 hours. * Preterm/ term premature rupture of membranes. * History of cervical injury/ surgery. * Hypersensitivity to valethamate bromide and/or hyoscine butyl bromide

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Labour duration are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Labour duration Primigravida

Contacts and locations

Locations

  • Alex Ekwueme Federal University Teaching Hospital

    Abakaliki, Ebonyi State, 480101, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.